---
title: "Placebo and mortality in Beta Blocker Eval of Survival Trial | Sutter Health"
description: "Analyses of the Beta Blocker Evaluation of Survival trial data support a strong association between adherence to placebo study medication and total mortality."
url: "https://www.sutterhealth.org/research/publications/placebo-and-mortality-in-beta-blocker-eval-of-survival-trial-1055312716"
---

1.  [Home](https://www.sutterhealth.org/) /
2.  [Research](https://www.sutterhealth.org/research) /
3.  [Research publications](https://www.sutterhealth.org/research/publications) /
4.  Placebo and mortality in Beta Blocker Eval of Survival Trial

# Adherence to placebo and mortality in the Beta Blocker Evaluation of Survival Trial (BEST).

Pressman A, Avins AL, Neuhaus J, Ackerson L, & Rudd P.

_Contemp Clin Trials. 33(3):492-8. doi: 10.1016/j.cct.2011.12.003. Epub 2012 Jan 12._

2012-05-01

## Abstract

BACKGROUND: Randomized controlled trials have reported lower mortality among patients who adhere to placebo compared with those who do not. We explored this phenomenon by reanalyzing data from the placebo arm of the Beta Blocker Evaluation of Survival Trial (BEST), a randomized, double-blind, placebo-controlled trial of bucindolol and mortality.

AIMS: Our primary aim was to measure and explain the association between adherence to placebo and total mortality among the placebo-allocated participants in the BEST trial. Secondary aims included assessment of the association between placebo adherence and cause-specific mortality.

METHODS: Participants with "higher placebo adherence" were defined as having taken at least 75% of their placebo study medication over the entire course of each individual's participation in the study, while those with "lower placebo adherence" took <75%. Primary outcome was in-study all-cause mortality. To account for confounding, we adjusted for all available modifiable, non-modifiable and psychosocial variables.

RESULTS: Adherent participants had a significantly lower total mortality compared to less-adherent participants (HR=0.61, 95% Confidence Interval: 0.46-0.82). Adjusting for available confounders did not change the magnitude or significance of the estimates. When considering cause-specific mortality, CVD and pump failure showed similar associations.

CONCLUSIONS: Analyses of the BEST trial data support a strong association between adherence to placebo study medication and total mortality. While probably not due to publication bias or simple confounding by healthy lifestyle factors, the underlying explanation for the association remains a mystery. Prospective examination of this association is necessary to better understand the underlying mechanism of this observation.

[PubMed abstract](https://www.ncbi.nlm.nih.gov/pubmed/?term=22265975)

## Research topics

-   [Aging and Longevity](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Aging+and+Longevity%5C%22%22)
-   [Cardiovascular Diseases](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Cardiovascular+Diseases%5C%22%22)

## Related publications

[View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication)

-   Publication
    
    ### [Pharmacotherapy in older adults with cardiovascular disease: report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging workshop.](https://www.sutterhealth.org/research/publications/pharmacotherapy-in-seniors-with-cardiovascular-disease-1055312371)
    
    Schwartz JB, Schmader KE, Hanlon JT, Abernethy DR, Gray S, Dunbar-Jacob J, Holmes HM, Murray MD, Roberts R, Joyner M, Peterson J, Lindeman D, Tai-Seale M, Downey L, Rich MW.
    
    J Am Geriatr Soc. 2018 Dec 7. doi: 10.1111/jgs.15634. \[Epub ahead of print\]
    
    2018 Dec 07
    
-   Publication
    
    ### [Thoracic aorta calcification and noncardiovascular disease-related mortality: the multi-ethnic study of atherosclerosis.](https://www.sutterhealth.org/research/publications/thoracic-aorta-calcification-and-non-cvd-mortality-1055312467)
    
    Thomas IC, Thompson CA, Yang M, Allison MA, Forbang NI, Michos ED, McClelland RL, Budoff MJ, Criqui MH.
    
    Arterioscler Thromb Vasc Biol. pii: ATVBAHA.118.310850. doi: 10.1161/ATVBAHA.118.310850. \[Epub ahead of print\]
    
    2018 Jun 28
    
-   Publication
    
    ### [Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: a systematic review and meta-analysis.](https://www.sutterhealth.org/research/publications/dabigatran-vs-warfarin-atrial-fibrillation-1055312522)
    
    Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB.
    
    Circ Cardiovasc Qual Outcomes. pii: CIRCOUTCOMES.115.002369. \[Epub ahead of print\]
    
    2016 Jan 26
    
-   Publication
    
    ### [Provider perspectives on advance care planning documentation in the electronic health record.](https://www.sutterhealth.org/research/publications/providers-on-advance-care-plans-ehr-1055312324)
    
    Dillon E, Chuang J, Gupta A, Tapper S, Lai S, Yu P, Ritchie C, Tai-Seale M.
    
    Am J Hosp Palliat Care. 1049909117693578. doi: 10.1177/1049909117693578. \[Epub ahead of print\]
    
    2017 Jan 01
    
-   Publication
    
    ### [Home blood pressure monitoring among adults—American Heart Association Cardiovascular Health Consumer Survey, 2012](https://www.sutterhealth.org/research/publications/home-blood-pressure-monitoring-among-adults-1055312805)
    
    The Journal of Clinical Hypertension
    
    2017 Jun 19
    

[View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication)

```json
{"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]}
```

```json
{"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/placebo-and-mortality-in-beta-blocker-eval-of-survival-trial-1055312716#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"Placebo and mortality in Beta Blocker Eval of Survival Trial"}]}
```

```json
{"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/placebo-and-mortality-in-beta-blocker-eval-of-survival-trial-1055312716#medicalscholarlyarticle","name":"Adherence to placebo and mortality in the Beta Blocker Evaluation of Survival Trial (BEST).","headline":"Placebo and mortality in Beta Blocker Eval of Survival Trial","abstract":"BACKGROUND: Randomized controlled trials have reported lower mortality among patients who adhere to placebo compared with those who do not. We explored this phenomenon by reanalyzing data from the placebo arm of the Beta Blocker Evaluation of Survival Trial (BEST), a randomized, double-blind, placebo-controlled trial of bucindolol and mortality. AIMS: Our primary aim was to measure and explain the association between adherence to placebo and total mortality among the placebo-allocated participants in the BEST trial. Secondary aims included assessment of the association between placebo adherence and cause-specific mortality. METHODS: Participants with \"higher placebo adherence\" were defined as having taken at least 75% of their placebo study medication over the entire course of each individual's participation in the study, while those with \"lower placebo adherence\" took \u003c75%. Primary outcome was in-study all-cause mortality. To account for confounding, we adjusted for all available modifiable, non-modifiable and psychosocial variables. RESULTS: Adherent participants had a significantly lower total mortality compared to less-adherent participants (HR=0.61, 95% Confidence Interval: 0.46-0.82). Adjusting for available confounders did not change the magnitude or significance of the estimates. When considering cause-specific mortality, CVD and pump failure showed similar associations. CONCLUSIONS: Analyses of the BEST trial data support a strong association between adherence to placebo study medication and total mortality. While probably not due to publication bias or simple confounding by healthy lifestyle factors, the underlying explanation for the association remains a mystery. Prospective examination of this association is necessary to better understand the underlying mechanism of this observation.","description":"Analyses of the Beta Blocker Evaluation of Survival trial data support a strong association between adherence to placebo study medication and total mortality.","keywords":["Aging and Longevity","Cardiovascular Diseases"],"datePublished":"2012-05-01","url":"https://www.sutterhealth.org/research/publications/placebo-and-mortality-in-beta-blocker-eval-of-survival-trial-1055312716","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"DOI","value":"10.1016/j.cct.2011.12.003"}],"sameAs":["https://doi.org/10.1016/j.cct.2011.12.003"],"isPartOf":{"@type":"Periodical","name":"Contemp Clin Trials"},"author":[{"@type":"Person","name":"Pressman A"},{"@type":"Person","name":"Avins AL"},{"@type":"Person","name":"Neuhaus J"},{"@type":"Person","name":"Ackerson L"},{"@type":"Person","name":"Rudd P"}],"sourceOrganization":{"@type":"MedicalOrganization","name":"Palo Alto Medical Foundation Research Institute"},"about":[{"@type":"DefinedTerm","name":"Aging and Longevity","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Aging+and+Longevity%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Cardiovascular Diseases","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Cardiovascular+Diseases%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/placebo-and-mortality-in-beta-blocker-eval-of-survival-trial-1055312716","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/placebo-and-mortality-in-beta-blocker-eval-of-survival-trial-1055312716#breadcrumblist"}}}
```
